# EDGAR Filing Document

**Accession Number:** 0001574094
**File Stem:** 0000000000-25-007937
**Filing Date:** 2025-7
**Character Count:** 5035
**Document Hash:** 9007302ff45609be580d14fb4ca3526e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007937.hdr.sgml**: 20251217

**ACCESSION NUMBER**: 0000000000-25-007937

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250729

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RenovoRx, Inc.
- **CENTRAL INDEX KEY:** 0001574094
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 271448452
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-40738

**BUSINESS ADDRESS:**
- **STREET 1:** 2570 W. EL CAMINO REAL, STE. 320,
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94040
- **BUSINESS PHONE:** 408-800-2649

**MAIL ADDRESS:**
- **STREET 1:** 2570 W. EL CAMINO REAL, STE. 320,
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94040
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001641172-25-001932

## Text-Extract

```

                                                           July 29, 2025

Ronald B. Kocak
VP Controller and Principal Accounting Officer
RenovoRx, Inc.
2570 West El Camino Real, Suite 320
Mountain View, California 94040

       Re: RenovoRx, Inc.
           Form 10-K for the fiscal year ended December 31, 2024
           Form 10-Q for the quarterly period ended March 31, 2025
           File No. 001-40738
Dear Ronald B. Kocak:

       We have reviewed your July 18, 2025 response to our comment letter and
have the
following comments.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.
Unless we note otherwise, any references to prior comments are to comments in
our July 10,
2025 letter.

Form 10-K for the fiscal year ended December 31, 2024
Controls and Procedures, page 87

1.     We have read your response to comment 1. Notwithstanding the correction
of the typo
       referring to "December 31, 2022" which relates specifically to the
evaluation of
       disclosure controls and procedures only, you were required to provide a
management
       report on internal control over financial reporting (ICFR) beginning
with your Form
       10-K for the year ended December 31, 2023, as that was when your
transition period
       of being a newly public company ended. The information provided on pages
87-88
       under section (b) of this Item 9A. does not constitute a management
report on ICFR as
       it does not comply with the disclosure requirements of Item 308(a) of
Regulation S-K.
       Therefore, please tell us management's assessment of effectiveness of
ICFR as of
       December 31, 2024 and, as previously requested, confirm that you will
revise your
       future filings to provide management   s conclusion regarding the
effectiveness of your
 July 29, 2025
Page 2

       internal control over financial reporting.

Form 10-Q for the quarterly period ended March 31, 2025
Item 2: Management's Discussion and Analysis of Financial Condition and Results
of
Operations, page 16
Results of Operations, page 20, page 90

2.     We have read your response to comment 2. You have told us, among other
things, that
       "all commercial costs for the production of the RenovoCath device in
connection with
       our commercialization program are capitalized on the balance sheet or
charged as cost
       of goods sold on the income statement." However, you disclose on page 21
that you
       anticipate selling, general and administrative expenses to increase
during 2025 as you
       progress with your commercialization activities for your RenovoCath
device. Please
       address the following:
           Please tell us the amount and the nature of the commercial costs
that were charged
           to cost of goods sold for the four most recent quarters and explain
how these costs
           are appropriately classified as cost of goods sold. Refer to ASC
330-10-30.
           Consider enhancing your disclosure of these amounts in future
filings.
           Also, tell us and consider revising your future filings to identify
the nature of the
           increased expenses in selling, general and administrative related to
the
           commercialization of your RenovoCath device.

       Please contact Jenn Do at 202-551-3743 or Vanessa Robertson at
202-551-3649 if
you have questions regarding comments on the financial statements and related
matters.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._